ArticleScience advances2022
DNA origami-based artificial antigen-presenting cells for adoptive T cell therapy.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 84 citations in OpenAlex.
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Programmable DNA Logic Systems for Applications in Biomedicine.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Discriminating Post-Transplant Rejection from Infection by Detecting TCR-CD3 Oligomerization on Extracellular Vesicles Using a Ratiometric Caliper Probe.Journal of the American Chemical Society · 2026Article
- Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges.Materials today. Bio · 2026Review
- Review
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- Ultra-Fast Isothermal Formation of DNA Nanostructures in Culture Media: Application to In Situ Assembly of DNA Origami With Living Cells.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Resolving DNA origami structural integrity and pharmacokinetics in vivo.Nature nanotechnology · 2026Article
- A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy.Chemical science · 2026Article
- Multivalent DNA Origami Enables Single-Molecule Dissection of Integrin αvβ6-Receptor Tyrosine Kinase Crosstalk in Cancer Biology.ACS nano · 2025Article
- Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies.Nature nanotechnology · 2025Review
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Evolution of multivalent supramolecular assemblies of aptamers with target-defined spatial organization.Nature nanotechnology · 2025Article
- DNA Origami-Based CD44-Targeted Therapy Silences Stat3 Enhances Cartilage Regeneration and Alleviates Osteoarthritis Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- [Biomaterials of different sizes for enhanced adoptive cell transfer therapy in solid tumors].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Advances in nanotechnology for targeting cancer-associated fibroblasts: A review of multi-strategy drug delivery and preclinical insights.APL bioengineering · 2025Review
- Frontiers in mechanobiology and mechanomedicine.Med-X · 2025Article
- Article
- Bottom-up synthetic immunology.Nature nanotechnology · 2024Review
- Fluidic Interface for Surface-based DNA Origami Studies.ACS applied materials & interfaces · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanosized artificial antigen-presenting cells (aAPCs) with efficient signal presentation hold great promise for in vivo adoptive cell therapy. Here, we used DNA origami nanostructures as two-dimensional scaffolds to regulate the spatial presentation of activating ligands at nanoscale to construct high-effective aAPCs. The DNA origami-based aAPC comprises costimulatory ligands anti-CD28 antibody anchored at three vertices and T cell receptor (TCR) ligands peptide-major histocompatibility complex (pMHC) anchored at three edges with varying density. The DNA origami scaffold enables quantitative analysis of ligand-receptor interactions in T cell activation at the single-particle, single-molecule resolution. The pMHC-TCR-binding dwell time is increased from 9.9 to 12.1 s with increasing pMHC density, driving functional T cell responses. In addition, both in vitro and in vivo assays demonstrate that the optimized DNA origami-based aAPCs show effective tumor growth inhibiting capability in adoptive immunotherapy. These results provide important insights into the rational design of molecular vaccines for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.